Skip to main content

Helicos' Shares Soar Day After Publication; CFO to Depart

NEW YORK (GenomeWeb News) – Shares of Helicos BioSciences closed up 40 percent on Tuesday, a day after the firm's technology was used to sequence the genome of one of its co-founders.

The paper, published in Nature Biotechnology, detailed how Stephen Quake, a Stanford University bioengineer and Helicos co-founder, sequenced his own genome using a single Heliscope machine and four data collection runs. He was able to achieve this feat in about four weeks at a cost of around $48,000 in sequencing reagents.

Investors reacted positively to the news, sending Helicos' shares as high as $1.70 during Tuesday's trading session, before closing at $1.01.

Helicos also disclosed Tuesday that its CFO, Stephen Hall, will be leaving the firm. Helicos said in a filing with the US Securities and Exchange Commission that Hall will leave that role after the firm files its form 10-Q, which is expected to occur this Friday, Aug. 14.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.